Samsung Bioepis Initiates Phase 3 Clinical Trial for SB17, Proposed Biosimilar to Stelara (Ustekinumab)
- Category: Antibodies
- Published on Monday, 19 July 2021 15:56
- Hits: 867
INCHEON, Korea I July 19 2021 I Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB17, the company's proposed biosimilar referencing Stelara (ustekinumab). The Phase 3 clinical trial for SB17 (ustekinumab) is a randomized, double-blind, multicenter clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of SB17 compared to Stelara in patients with moderate to severe plaque psoriasis. More information on this study is available at clinicaltrials.gov (NCT#04967508).
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology. For more information, please visit: www.samsungbioepis.com and follow us on social media–Twitter, LinkedIn.
SOURCE: Samsung Bioepis